Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study

Archives of Virology

Volumn 160, Issue 4, 2015, Pages 929-936

  Dong, Yuan ^a   Qiu, Chao ^a   Xia, Xueshan ^b   Wang, Jing ^a   Zhang, Haiyan ^c   Zhang, Xiaoyan ^a   Xu, Jianqing ^a  

^a FUDAN UNIVERSITY   (China)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Dali Municipal Centers for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; BLOOD; CD4 LYMPHOCYTE COUNT; CHINA; COINFECTION; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PHYSIOLOGY; PREVALENCE; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHINA; COINFECTION; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84925466765     PISSN: 03048608     EISSN: 14328798     Source Type: Journal    
DOI: 10.1007/s00705-014-2311-0     Document Type: Article

References (39)

1. Anderson KB, Guest JL, Rimland D (2004) Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 39:1507–1513
2. Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, Wang SH, You LR, Lee YH (2003) Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 278:591–607
3. Gebo KA, Diener-West M, Moore RD (2003) Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 34:165–173
4. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA, Santantonio T, Pape GR (1999) Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117:933–941
5. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33:562–569
6. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800–1805
7. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91
8. Hoffmann CJ, Thio CL (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7:402–409
9. Kobayashi Y, Kawaguchi Y, Mizuta T, Kuwashiro T, Oeda S, Oza N, Takahashi H, Iwane S, Eguchi Y, Anzai K, Ozaki I, Fujimoto K (2011) Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. J Gastroenterol 46:529–535
10. Liaw YF (1995) Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology (Baltimore, Md) 22:1101–1108
11. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH (2005) Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 75:538–549
12. Maio G, d’Argenio P, Stroffolini T, Bozza A, Sacco L, Tosti ME, Intorcia M, Fossi E, d’Alessio G, Kondili LA, Rapicetta M, Mele A (2000) Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol 33:116–120
13. Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD (2009) Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr 51:574–581
14. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571–583
15. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, Alberti A (1993) Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 105:1529–1533
16. Pratt DS, Kaplan MM (2000) Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342:1266–1271
17. Ruan YH, Hong KX, Liu SZ, He YX, Zhou F, Qin GM, Chen KL, Xing H, Chen JP, Shao YM (2004) Community-based survey of HCV and HIV coinfection in injection drug abusers in Sichuan Province of China. World J Gastroenterol 10:1589–1593
18. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, Scolastico C, Filippini P (2006) Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 35:317–320
19. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V, Filippini P (2009) HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology (Baltimore, Md) 49:1090–1097
20. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S (2002) Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 37:855–862
21. Sheen IS, Liaw YF, Chu CM, Pao CC (1992) Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 165:831–834
22. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH (1993) Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 67:5823–5832
23. Simmonds P (1995) Variability of hepatitis C virus. Hepatology (Baltimore, Md) 21:570–583
24. Simmonds P (2001) The origin and evolution of hepatitis viruses in humans. J Gen Virol 82:693–712
25. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J (2008) Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 198:1337–1344
26. Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, Di Marco V, Picciotto A, Colucci G, Craxi A, Raimondo G (2002) Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 97:1518–1523
27. Sterling RK, Sulkowski MS (2004) Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin Liver Dis 24(Suppl 2):61–68
28. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology (Baltimore, Md) 39:1147–1171
29. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL (2002) Hepatitis C and progression of HIV disease. JAMA 288:199–206
30. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (Baltimore, Md) 35:182–189
31. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921–1926
32. Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, Smith J, McClure MO, Karayiannis P (2011) Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 60:837–845
33. Verucchi G, Calza L, Manfredi R, Chiodo F (2004) Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 32:33–46
34. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166:1632–1641
35. Wietzke P, Schott P, Braun F, Mihm S, Ramadori G (1999) Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 19:348–353
36. Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn CH, Takebe Y (2008) The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol 80:1142–1152
37. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D (1998) Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 28:27–33
38. Zhang C, Yang R, Xia X, Qin S, Dai J, Zhang Z, Peng Z, Wei T, Liu H, Pu D, Luo J, Takebe Y, Ben K (2002) High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr 29:191–196
39. Zhou YH, Liu FL, Yao ZH, Duo L, Li H, Sun Y, Zheng YT (2011) Comparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS ONE 6:e16349